RT Journal Article
SR Electronic
T1 When to relax a lockdown? A modelling-based study of testing-led strategies coupled with sero-surveillance against SARS-CoV-2 infection in India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.29.20117010
DO 10.1101/2020.05.29.20117010
A1 Mandal, Sandip
A1 Das, Hemanshu
A1 Deo, Sarang
A1 Arinaminpathy, Nimalan
YR 2020
UL http://medrxiv.org/content/early/2020/05/30/2020.05.29.20117010.abstract
AB India’s lockdown against SARS-CoV-2, if lifted without any other mitigations in place, could risk a second wave of infection. A test-and-isolate strategy, using PCR diagnostic tests, could help to minimise the impact of this second wave. Meanwhile, population-level serological surveillance can provide valuable insights into the level of immunity in the population. Using a mathematical model, consistent with an Indian megacity, we examined how seroprevalence data could guide a test-and-isolate strategy, for lifting a lockdown. For example, if seroprevalence is 20% of the population, we show that a testing strategy needs to identify symptomatic cases within 5 – 8 days of symptom onset, in order to prevent a resurgent wave from overwhelming hospital capacity in the city. This estimate is robust to uncertainty in the effectiveness of the lockdown, as well as in immune protection against reinfection. To set these results in their economic context, we estimate that the weekly cost of such a PCR-based testing programme would be less than 2.1% of the weekly economic loss due to the lockdown. Our results illustrate how PCR-based testing and serological surveillance can be combined to design evidence-based policies, for lifting lockdowns in Indian cities and elsewhere.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNA was funded by the UK Medical Research Council (MRC) and the Bill and Melinda Gates Foundation (BMGF).The funder had no role in study design, interpretation of results or publication decisions.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data generated or analysed during this study are included in this published article and its supplementary information file.